Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy

NCT04429022
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Acetaminophen, Celecoxib, Ketorolac, Paracervical block with ropivacaine, Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites, Hydromorphone, Oxycodone
Drug · Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
25 Years to 90 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers

NCT01981395
View directory record Official record
Conditions
Hyperalgesia, Allodynia
Interventions
Fenobam, Placebo
Drug
Lead sponsor
Laura Cavallone
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 26, 2026, 3:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Not applicable Interventional Results available

A Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants

NCT04419857
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High-calorie formula
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Terminated Not applicable Interventional

Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome

NCT04428567
View directory record Official record
Conditions
Fragile X Associated Tremor-ataxia Syndrome
Interventions
Dual-Task Treadmill exercise + Cognitive Training
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Not applicable Interventional

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

NCT02646488
View directory record Official record
Conditions
Cardiovascular Disease, High Blood Pressure
Interventions
Million Hearts ABCS 6 Months, Million Hearts ABCS 9 Months, Million Hearts ABCS 12 Months, Million Hearts ABCS 15 Months, Standard Care Regimen 9 Months, Standard Care Regimen 12 Months, Standard Care Regimen 15 Months, Standard Care Regimen 18 Months, Standard Care Regimen 21 Months, Standard Care Regimen 24 Months, Standard Care Regimen 27 Months, Follow Up Post Intervention 21 Months, Follow Up Post Intervention 24 Months, Follow Up Post Intervention 27 Months, Follow Up Post Intervention 30 Months, Follow Up Post Intervention 33 Months
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Oct 26, 2026, 3:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536
View directory record Official record
Conditions
Crohn's Disease
Interventions
brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Escondido, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Video Game Play to Alleviate Adolescent Anxiety

NCT05923944
View directory record Official record
Conditions
Anxiety, Anxiety Disorders and Symptoms
Interventions
Eco-Rescue, Bejelewed 3
Behavioral
Lead sponsor
School of Health Sciences Geneva
Other
Eligibility
11 Years to 15 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Not applicable Interventional

Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents

NCT03199716
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Parent mentors
Other
Lead sponsor
University of California, Davis
Other
Eligibility
10 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 4 Interventional Results available

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

NCT03078907
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057, Placebo
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

NCT02673567
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

NCT00317642
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation), placebo, cytarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
55 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 26, 2026, 3:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

NCT03829241
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
53
States / cities
Little Rock, Arkansas • Colton, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Not applicable Interventional Results available

Intermittent Fasting Adherence and Self Tracking

NCT04836312
View directory record Official record
Conditions
Hypertension, Obesity
Interventions
Soft Commitment Device
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Not applicable Interventional

Hypertension Management Using Telemonitoring

NCT03700775
View directory record Official record
Conditions
Hypertension
Interventions
Remote Telemonitoring
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

NCT00307437
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 2 Interventional

Mobile Technology and Online Tools to Track Adherence in Chronic Illness Patients

NCT02864641
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
Planet K
Behavioral
Lead sponsor
3-C Institute for Social Development
Industry
Eligibility
12 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 26, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Patients With Uncontrolled Hypertension

NCT05137002
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 26, 2026, 3:22 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR445399, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 3:22 AM EDT